Primary Catalyst Driving Choroidal Neovascularization Market Evolution in 2025: Increasing Prevalence Of Age-related Macular Degeneration Driving Market Growth Driver

What market dynamics are playing a key role in accelerating the growth of the choroidal neovascularization market?
The rising prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the choroidal neovascularization (CNV) market. AMD is a leading cause of central vision loss in older adults, and it is primarily influenced by aging, lifestyle factors, genetics, and exposure to environmental risks. One of the most severe manifestations of AMD is wet AMD, which is associated with choroidal neovascularization (CNV), where abnormal blood vessels grow beneath the retina, causing vision deterioration. Treatments such as anti-VEGF therapy are crucial for managing CNV and slowing AMD progression. With the global aging population and the growing incidence of AMD, projections indicate that by 2040, there may be 300 million cases of AMD. As a result, the increasing prevalence of AMD is driving the growth of the CNV market.

Get Your Choroidal Neovascularization Market Report Here:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

How will the growth rate of the choroidal neovascularization market shape industry trends by 2034?
The choroidal neovascularization market has grown strongly, expected to expand from $3.37 billion in 2024 to $3.61 billion in 2025, with a CAGR of 8.1%. Key historical growth drivers include an increase in sedentary lifestyle diseases, rising cases of age-related macular degeneration, a growing incidence of retinal illnesses, an aging population, rising eye care costs, and expanding screening initiatives.

The choroidal neovascularization market is anticipated to see steady growth, reaching $5.64 billion by 2029 at a CAGR of 7.7%. Growth drivers include increasing patient awareness, wider adoption of optical coherence tomography angiography, a rising demand for minimally invasive procedures, favorable reimbursement policies, and an expanding elderly population. Key trends in the forecast period include the emergence of intravitreal anti-VEGF therapies, the development of new gene-based treatments, advancements in gene therapy approaches, the growing use of telemedicine, the introduction of combination therapies, and the evolution of personalized treatment strategies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

What trends are poised to drive the future success of the choroidal neovascularization market?
Leading companies in the choroidal neovascularization market are working on developing advanced therapies, such as photodynamic therapy, to offer eye care professionals precise and efficient treatment options that enhance patient outcomes and treatment effectiveness. Photodynamic therapy (PDT) uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For example, in February 2023, Bausch & Lomb, a healthcare company from Canada, and Modulight, a biomedical company from Finland, announced the FDA-approved ML6710i photodynamic laser. This therapy, in combination with Bausch + Lomb's VISUDYNE therapy, is designed to treat choroidal neovascularization caused by age-related macular degeneration (AMD). The modern, mobile ophthalmic laser provides a targeted approach to treating abnormal blood vessels in the eye, helping prevent further disease progression and preserving vision.

Which primary segments of the choroidal neovascularization market are driving growth and industry transformations?
The choroidal neovascularization market covered in this report is segmented -

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications
3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral
4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

Which geographical regions are pioneering growth in the choroidal neovascularization market?
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the influential players reshaping the choroidal neovascularization market landscape?
Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

What Is Covered In The Choroidal Neovascularization Global Market Report?

•Market Size Forecast: Examine the choroidal neovascularization market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the choroidal neovascularization market for a structured understanding.
•Key Players Overview: Analyze major players in the choroidal neovascularization market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the choroidal neovascularization market.
•Segment Contributions: Evaluate how different segments drive overall growth in the choroidal neovascularization market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the choroidal neovascularization market.
•Industry Challenges: Identify potential risks and obstacles affecting the choroidal neovascularization market.
•Competitive Landscape: Review strategic developments in the choroidal neovascularization market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.